Birchview Capital’s Kyntra Bio KYNB Stock Holding History

Birchview Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$170K	Hold	22,566	–	–	0.08%	67
2026 Q1	$153K	Buy	+22,566	New	+$177K	0.09%	68

Other funds holding KYNB

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Birchview Capital's KYNB Position: Q2 2026 in Review

Birchview Capital held its Kyntra Bio (KYNB) position steady in Q2 2026 at 22,566 shares worth $170K. The position accounts for 0.08% of the portfolio, ranked #67.

Birchview Capital first reported a position in KYNB in Q1 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

Birchview Capital held 22,566 shares of Kyntra Bio worth $170K as of Q2 2026.
Birchview Capital left its Kyntra Bio share count unchanged in Q2 2026.
Kyntra Bio made up 0.08% of Birchview Capital's portfolio in Q2 2026, its #67 holding.
Birchview Capital first reported a position in Kyntra Bio in Q1 2026 and has held it in 2 quarters since.
27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.